GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Carbogen Amcis Manchester won the industry award in recognition of its efficiency improvement program implemented in response to increased demand for its products
Dr. Reddy's aims to roll out its trade generics across cities and towns in India
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.
Effective disaster response and management is a collaborative work
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
The investment is part of Croda’s continuing commitment to develop high performance pharmaceutical ingredients and technologies for life sciences.
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Approximately 60 to 78% of individuals diagnosed with Asthma also have concurrent Allergic Rhinitis
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
The increased drug load enabled by the nanoformed particles also allows smaller implants with sustained release properties to be developed.
Cullgen will have the option during the initial stages of clinical development to participate equally in the costs, profits and losses
Subscribe To Our Newsletter & Stay Updated
